Overview
Bryan Ball, who serves as Chief Technical Operations Officer and Senior Vice President, Manufacturing Operations at Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), sold a combined 118,849 shares of the company's common stock across two transactions on April 13 and April 14, 2026. The trades produced proceeds totaling $427,860, with execution prices ranging from $3.46 to $3.64 per share. The transactions were disclosed on a Form 4 filed with the Securities and Exchange Commission.
Transaction details
On April 13, Ball sold 26,389 shares at a price of $3.46 per share. Immediately after that sale, Ball retained direct ownership of 489,566 shares. The following day, April 14, he sold an additional 92,460 shares at $3.64 per share, reducing his direct holdings to 397,106 shares. Company filings indicate the sales were broker-assisted and completed to meet tax obligations arising from the vesting of restricted stock units.
Share price and valuation context
Whitehawk's stock has risen 153% over the prior 12 months and is trading at $3.90. An InvestingPro analysis cited within company-related commentary places a Fair Value for the stock at $4.87 and lists the company among the most undervalued names in its coverage. That analysis also notes 12 additional tips for WHWK and references a Pro Research Report that includes this company alongside more than 1,400 other U.S. equities.
Clinical research update
In separate corporate disclosures, Whitehawk presented data at the Society of Gynecologic Oncology 2026 Annual Meeting addressing expression patterns of the MUC16 target in ovarian and endometrial cancers. The analysis, carried out in collaboration with Tempus AI, reported that MUC16 expression in ovarian cancer is substantially higher than that of several other antibody-drug conjugate (ADC) targets — specifically NaPi2b, HER2, FRα, TROP2, B7-H4, CDH6, and CLDN6.
The presentation indicated that MUC16 expression remains stable across different disease stages, metastatic status, and platinum sensitivity for high-grade serous ovarian carcinoma. The company noted that this histologic subtype accounts for roughly 70% of ovarian cancer cases. The findings were described as supportive of MUC16's potential role as a target for ADC therapies in ovarian cancer and were framed as part of Whitehawk's ongoing oncology research efforts.
Implications and closing
The insider sales were explicitly tied to tax liabilities from RSU vesting, according to the Form 4 filing. The transactions and the clinical data presentation were reported as distinct corporate activities in the same timeframe.
Note: The article reports company disclosures and regulatory filings as provided; it neither offers investment advice nor adds interpretation beyond those disclosures.